COMMUNIQUÉS West-GlobeNewswire

Ambu A/S: Ambu launches 4th generation of single-use bronchoscopes

25/09/2017 - 07:59

Innovation: 'Ambu ® aScope TM 4 Broncho' unveiled today in Vienna at European intensive care congress. Improved image quality means that Ambu expects new scope to be relevant for 50% more hospital procedures. Over the [...]

Targovax granted US Patent for mutant-RAS neoantigen platform lead products

25/09/2017 - 07:00

Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]

IBA SA : IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie

23/09/2017 - 16:00

IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie SAN DIEGO, Etats-Unis, 23 septembre 2017 - IBA (Ion Beam [...]

IBA SA : IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments

23/09/2017 - 16:00

IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments SAN DIEGO, September 23, 2017 - IBA (Ion Beam Applications) and [...]

Abiomed obtient l'autorisation APMM de la FDA pour l'Impella RP® pour l'insuffisance cardiaque droite

22/09/2017 - 23:53

DANVERS, Massachusetts, le 22 septembre 2017 (GLOBE NEWSWIRE) - Abiomed, Inc. (NASDAQ : ABMD), fournisseur majeur de technologies innovantes d'assistance et de récupération cardiaque, a annoncé aujourd'hui qu'elle a [...]

Le portefeuille de propriété intellectuelle de Merus s'enrichit de deux nouveaux brevets grâce à sa technologie Biclonics®

22/09/2017 - 16:27

UTRECHT, Pays-Bas, le 20 septembre 2017 (GLOBE NEWSWIRE). -- Merus (NASDAQ : MRUS), société spécialisée en immuno-oncologie au stade clinique qui développe des traitements visant à guérir des maladies graves, a annoncé [...]

CEO Jyrki Eklund takes over the responsibilities of Aino Health Sweden AB

22/09/2017 - 15:30

Aino Health has progressed as planned in the internationalisation process. In the first part of this year, we have been able to develop both the Swedish and German markets. Structures are now in good shape in the [...]

Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus

22/09/2017 - 14:00

Trial now includes more than 730 patients under previously announced amended protocol Top-line results from TACTT3 expected in first quarter 2018 Zug, Switzerland, September 22, 2017 - Auris Medical Holding AG (NASDAQ: [...]

AroCell AB: TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium

22/09/2017 - 11:30

AroCell AB (publ) announces today that an abstract submitted Kiran Kumar Jagarlamudi et al entitled "The AroCell TK 210 ELISA provides new information concerning the mechanism of anti-cancer drugs by determining the TK1 [...]

Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

22/09/2017 - 11:00

Heidelberg, Germany, September 22, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. [...]

Zealand increases its share capital as a consequence of exercise of employee warrants

22/09/2017 - 09:10

Company announcement - No. 46 / 2017 Zealand increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 22, 2017 - Zealand has increased its share capital by a nominal amount of [...]

Solon Eiendom ASA : Primary insider notification

22/09/2017 - 08:30

(Oslo, Norway, 21 September 2017) Per Knut Asphaug Bernhardt, personal assistant to the chairman of the board of Solon Eiendom ASA, (through his wholly owned company Factum AS) has today acquired a forward contract with [...]

Participation de XBiotech à la conférence Global Healthcare de Cantor Fitzgerald

22/09/2017 - 08:28

AUSTIN, Texas, le 22 septembre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) a annoncé aujourd'hui la participation de sa direction à la conférence Global Healthcare de Cantor Fitzgerald qui se tiendra du 25 au 27 [...]

Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs

22/09/2017 - 07:30

ORION CORPORATION PRESS RELEASE 22 SEPTEMBER 2017 at 8.30 EEST Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs Orion Pharma scientists [...]

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

22/09/2017 - 07:15

CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has provided approximately 75, [...]

Invitation to the extraordinary shareholders' meeting

22/09/2017 - 07:00

September 22, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Bone Therapeutics SA and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

22/09/2017 - 07:00

Regulated information Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB ® in Japan Asahi Kasei obtains exclusive license for the development and commercialisation of PREOB ® in Japan Option to [...]

Bone Therapeutics SA et Asahi Kasei signent un accord de licence exclusive portant sur PREOB® au Japon

22/09/2017 - 07:00

Information réglementée Bone Therapeutics et Asahi Kasei signent un accord de licence exclusive portant sur PREOB ® au Japon Licence exclusive délivrée à Asahi Kasei pour le développement et la commercialisation de [...]

Merus annonce ses résultats financiers du deuxième trimestre 2017 et souligne ses récents progrès

22/09/2017 - 00:50

UTRECHT, Pays-Bas, le 22 septembre 2017 (GLOBE NEWSWIRE). - Merus N.V. (NASDAQ : MRUS), entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics [...]